Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29083534 | 0.98 | LMNA (0.39) | OPRM1LMNADNM1CA2SMPD1 | |
| SCHEMBL1321198 | 0.98 | LMNA (0.39) | OPRM1LMNADNM1CA2SMPD1 | |
| SCHEMBL2907191 | 0.98 | LMNA (0.39) | OPRM1LMNADNM1CA2SMPD1 | |
| SCHEMBL4451765 | 0.92 | DNM1 (0.36) | LMNADNM1CA2FDPSTSHR | |
| SCHEMBL28471373 | 0.85 | OPRM1 (0.39) | OPRM1LMNADNM1CA2SMPD1 | |
| SCHEMBL7901136 | 0.83 | LMNA (0.39) | OPRM1LMNADNM1CA2SMPD1 | |
| SCHEMBL11686625 | 0.83 | LMNA (0.39) | OPRM1LMNADNM1CA2SMPD1 | |
| SCHEMBL8462298 | 0.81 | — | — | |
| SCHEMBL9750786 | 0.81 | OPRM1 (0.36) | OPRM1LMNADNM1CA2SMPD1 | |
| SCHEMBL27805623 | 0.79 | OPRM1 (0.34) | OPRM1LMNADNM1CA2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186531-B2 | Production method for alkene | KUREHA CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | KUREHA CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| US-7638585-B2 | Catalyst flow | BASF CATALYSTS, LLC (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090286942-A1 | CATALYST FLOW | BASF CATALYSTS LLC (US) | 2009-11-19 | — | — | US | disclosed |
| US-7135531-B2 | Spherical catalyst for olefin polymerization | BASF CATALYSTS LLC (US) | 2006-11-14 | — | — | US | disclosed |
| US-20050176900-A1 | Spherical catalyst for olefin polymerization | ENGELHARD CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-0284005-B1 | METHOD OF PRODUCTION OF POLYOLEFINS | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4981930-A | POLYMERIZATION CATALYSTS | IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0284005-A2 | Method of production of polyolefins | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | ALK, ALKBH3, ALKBH1 | OPRM1 4188/4885LMNA 1863/4885DNM1 3753/4885 |
| US-11186531-B2 | Production method for alkene | ALK, ALKBH3, ALKBH1 | OPRM1 4188/4885LMNA 1863/4885DNM1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.